REGENXBIO Announces Presentations at the American Society of Gene and Cell Therapy's 24th Annual Meeting
Oral presentations include:
Abstract Title: Effects of Sexual Dimorphism and Genetic Background on AAV Tissue Transduction in
Presenter:
Session Title: Novel Factors in AAV Transduction and AAV Genomes
Date/Time: Wednesday, May 12, 2021 from
Abstract Title: Intravenous Administration of a Barcoded and Pooled AAV Library for the Comprehensive Characterization and Comparison of Capsid Tropisms (abstract #189)
Presenter:
Session Title: Novel AAV Biology and Platform Technologies
Date/Time:
Abstract Title: High-Throughput Screening of AAV Productivity to Enable Rapid Capsid Characterization (abstract #192)
Presenter:
Session Title: Novel AAV Biology and Platform Technologies
Date/Time: Thursday, May 13, 2021 from
Abstract Title: RGX-121 Gene Therapy for the Treatment of Severe Mucopolysaccharidosis Type II: Interim Analysis of the First in Human Study (abstract #215)
Presenter: Roberto Giugliani, M.D., Ph.D., Professor, Department of Genetics, UFRGS, Medical Genetics Service, HCPA,
Session Title: Gene Therapy for Lysosomal Storage Disorders
Date/Time: Friday, May 14, 2021 from
Poster presentations include:
Abstract Title: Identification of Transcriptional Start Sites in a Tandem Promoter by 5'-RACE and NGS (abstract #317)
Presenter:
Session Title: AAV Vectors - Virology and Vectorology
Date/Time: Tuesday, May 11, 2021 from
Abstract Title: Comparative Cardiac, Neurologic, and Skeletal Effectiveness of Intravenous and Intrathecal AAV9-IDUA Delivered Individually or Combined in a Murine Model of Mucopolysaccharidosis Type I (abstract #490)
Presenter:
Session Title: Metabolic, Storage, Endocrine, Liver and Gastrointestinal Diseases
Date/Time: Tuesday, May 11, 2021 from
Abstract Title: Comprehensive Evaluation of an
Presenter:
Session Title: Neurologic Diseases
Date/Time: Tuesday, May 11, 2021 from
Abstract Title: RGX-202, an AAV8 Vector Encoding an
Presenter:
Session Title: Musculo-Skeletal Diseases
Date/Time: Tuesday, May 11, 2021 from
Abstract Title: A Novel AAV8 Vector for Microdystrophin Gene Therapy of Duchenne Muscular Dystrophy: Preclinical Studies in the MDX Mouse (abstract #614)
Presenter:
Session Title: Musculo-Skeletal Diseases
Date/Time: Tuesday, May 11, 2021 from
Abstract Title: A Case Study on Viral Clearance for a Downstream AAV Process using a
Presenter:
Session Title: Pharmacology/Toxicology Studies or
Date/Time: Tuesday, May 11, 2021 from
Abstract Title: Assessment of Inflammatory and Neurodegenerative Biomarkers in NHPs with DRG Toxicity (abstract #889)
Presenter:
Session Title: Pharmacology/Toxicology Studies or
Date/Time: Tuesday, May 11, 2021 from
Abstract Title: Quantification of Double-Stranded RNAs Produced by AAV Vectors: A Methodological Reassessment (abstract #891)
Presenter:
Session Title: Pharmacology/Toxicology Studies or
Date/Time: Tuesday, May 11, 2021 from
Abstract Title: Identification of a Kidney Specific AAV Following Insertion of Tissue Homing Peptides in Variable Region IV (abstract #292)
Presenter:
Session Title: AAV Vectors - Virology and Vectorology
Date/Time: Tuesday, May 11, 2021 from
About REGENXBIO Inc.
Contacts:
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com
Investors:
brendan@argotpartners.com
Media:
david.rosen@argotpartners.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/regenxbio-announces-presentations-at-the-american-society-of-gene-and-cell-therapys-24th-annual-meeting-301278430.html
SOURCE